Johnson & Johnson

https://www.jnj.com/

Johnson & Johnson is an American multinational corporation specializing in pharmaceutical, biotechnology, and medical technologies. Founded in 1886, the company's mission is to improve human health and well-being globally, focusing on enhancing access, affordability, and fostering healthier communities. Its world headquarters are located in New Brunswick, New Jersey, U.S.

Following the spin-off of its consumer health business (Kenvue) in 2023, Johnson & Johnson now primarily operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment develops treatments across therapeutic areas such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism. The MedTech segment focuses on interventional solutions, orthopedics, surgery, and vision care technologies.

Led by Chairman and CEO Joaquin Duato, Johnson & Johnson maintains a strong market position as one of the world's most valuable companies, holding a prime credit rating of AAA. The company was ranked No. 48 on the 2025 Fortune 500 list and 42nd in the 2025 Forbes Global 2000. Recent strategic moves include significant acquisitions, such as Shockwave Medical in 2025 and Abiomed in 2022, reinforcing its focus on high-growth areas like oncology and cardiovascular technology. Johnson & Johnson continues to emphasize a robust pipeline and aims to be the leading oncology company by 2030.

Latest updates

J&J Promotes Internal Finance Leader to Investor Relations

Event summary

  • Ryan Koors has been appointed Vice President, Investor Relations at Johnson & Johnson, effective May 7, 2026.
  • Koors succeeds Darren Snellgrove, who is departing to become CFO of Halozyme.
  • Koors has held multiple finance leadership roles within J&J since 2002, including CFO for Innovative Medicine Global Research & Development.
  • He holds a bachelor’s degree in finance and an MBA.

The big picture

The appointment of an internal candidate to Investor Relations signals a focus on operational alignment and financial rigor at Johnson & Johnson. With a market capitalization exceeding $350 billion, J&J’s investor relations strategy is critical for maintaining shareholder confidence and navigating a complex regulatory and competitive landscape. The move also highlights the ongoing churn in senior finance roles across the biopharma sector, as executives seek new opportunities.

What we're watching

Internal Succession
The promotion from within suggests a desire for continuity and alignment with existing strategic priorities, potentially limiting a fresh perspective on investor messaging.
Financial Focus
Koors’s extensive finance background across multiple divisions indicates a heightened emphasis on financial discipline and performance metrics in investor communications.
Halozyme Impact
The departure of Snellgrove to Halozyme warrants monitoring for any potential shifts in competitive dynamics or shared investor perspectives between the two companies.

J&J to Address Investors at Bernstein Conference Amid Portfolio Realignment

Event summary

  • Johnson & Johnson will participate in Bernstein’s 42nd Annual Strategic Decisions Conference.
  • The conference will be held on May 27, 2026.
  • Management will participate in a Fireside Chat at 11:00 a.m. Eastern Time.
  • A live webcast and archived recording will be available on J&J’s Investor Relations website.

The big picture

Johnson & Johnson’s participation in the Bernstein conference comes as the company continues to reshape its business following the significant spin-off of its consumer health division, Kenvue. This event provides a key opportunity for management to communicate its strategic vision and address investor concerns regarding the company’s future growth trajectory. The conference is a well-regarded forum for in-depth discussions of corporate strategy, suggesting Bernstein views J&J as a significant entity worthy of focused analysis.

What we're watching

Portfolio Focus
The content of the Fireside Chat will likely reveal further details regarding J&J’s ongoing portfolio restructuring and capital allocation priorities following the Kenvue spin-off.
Growth Strategy
Management’s commentary will be scrutinized for indications of how J&J intends to drive growth in its remaining pharmaceutical and medtech businesses, particularly given recent patent expirations and competitive pressures.
Investor Sentiment
The market’s reaction to the conference presentation will reflect investor confidence in J&J’s ability to execute its strategic plan and deliver sustainable returns.

J&J Gains CE Mark for ETHICON™ 4000 Stapler, Targeting Surgical Complication Costs

Event summary

  • Johnson & Johnson received CE Mark approval for the ETHICON™ 4000 Stapler on April 22, 2026.
  • The stapler utilizes proprietary 3D Stapling Technology and is designed for open, laparoscopic, and robotic surgery.
  • The ETHICON™ 4000 Stapler is intended to address surgical complications like leaks and bleeding, which can lead to significant costs.
  • Benchtop testing indicates reliable staple line integrity across a tissue thickness range of 1.0mm to 4.0mm.

The big picture

The approval of the ETHICON™ 4000 Stapler underscores the ongoing focus within the MedTech sector on minimizing surgical complications and associated costs. The device’s design, targeting a wide range of tissue thicknesses and compatibility with robotic systems, positions J&J to capture a larger share of the ~$10 billion global surgical stapler market. The company’s prior data suggesting improved outcomes with its stapling devices since 2017 provides a foundation for marketing and adoption, but real-world validation will be key.

What we're watching

Integration Risk
The successful integration of the ETHICON™ 4000 Stapler with the OTTAVA™ Robotic Surgical System will be critical for maximizing market penetration and realizing the full potential of the technology.
Clinical Validation
Real-world clinical data demonstrating the ETHICON™ 4000 Stapler’s impact on patient outcomes and complication rates will be essential to drive adoption and differentiate it from existing solutions.
Cost Savings
The extent to which the ETHICON™ 4000 Stapler can demonstrably reduce surgical complication costs, as highlighted in the press release, will influence its adoption rate among hospitals and surgeons.

J&J's AI-Powered CARTOSOUND SONATA Aims to Streamline Cardiac Mapping

Event summary

  • Johnson & Johnson launched CARTOSOUND SONATA at the 2026 Heart Rhythm Society (HRS) Annual Meeting, integrating AI with the CARTO System.
  • CARTOSOUND SONATA automatically transforms intracardiac echocardiography (ICE) images into detailed cardiac maps, identifying and labeling structures.
  • The module integrates with SOUNDSTAR CRYSTAL and NUVISION NAV ultrasound catheters, supporting procedures for atrial fibrillation, ventricular tachycardia, and complex concomitant procedures.
  • This launch coincides with the 30th anniversary of the CARTO System, highlighting its evolution and foundational role in electrophysiology.

The big picture

J&J’s CARTOSOUND SONATA represents a strategic move to leverage AI in a mature market—electrophysiology—where procedural efficiency and accuracy are paramount. The company’s focus on integrating AI into the established CARTO platform, rather than developing a completely new system, minimizes risk but also requires demonstrating a clear advantage over existing solutions. This aligns with a broader trend in MedTech towards AI-powered diagnostics and therapeutics, which is attracting significant investment and driving consolidation within the industry.

What we're watching

Adoption Rate
The speed at which hospitals and electrophysiologists adopt CARTOSOUND SONATA will determine its impact on J&J’s electrophysiology revenue and market share.
Competitive Response
Competitors like EnSite will likely accelerate their own AI-driven imaging solutions, potentially eroding J&J’s competitive advantage in cardiac mapping.
Clinical Validation
Continued clinical data demonstrating improved patient outcomes and workflow efficiency will be crucial for securing reimbursement and widespread adoption of CARTOSOUND SONATA.

J&J's TECNIS PureSee IOL Data Bolsters EDOF Lens Market Position

Event summary

  • Johnson & Johnson presented data at the 2026 ASCRS Annual Meeting supporting the performance of its TECNIS PureSee intraocular lens (IOL).
  • Two studies, one post-market observation (293 patients across 19 sites) and one U.S. clinical trial (200 patients across nine sites), demonstrated improved visual outcomes and patient satisfaction.
  • The post-market study showed 96% spectacle independence for distance, 95% for intermediate, and 61% for near vision.
  • Clinical trial data showed improved intermediate vision compared to monofocal IOLs, with comparable distance visual acuity.

The big picture

The TECNIS PureSee IOL represents Johnson & Johnson’s continued investment in the premium cataract surgery market, a segment driven by aging populations and a desire for reduced reliance on corrective eyewear. The data presented reinforces J&J’s position in the EDOF IOL space, but the market remains competitive, with other players vying for surgeon preference and patient adoption. Success hinges on demonstrating a clear clinical advantage and securing favorable reimbursement.

What we're watching

Market Adoption
The pace at which surgeons adopt TECNIS PureSee will determine its impact on J&J’s ophthalmology revenue, especially given the competitive landscape of EDOF IOLs.
Reimbursement
Whether payers will favorably reimburse TECNIS PureSee based on the presented clinical data will be crucial for broader market penetration.
Competitive Response
Competitors will likely respond with their own EDOF lens innovations, potentially intensifying the competition for market share in the premium cataract surgery segment.

J&J Launches VARIPULSE Pro in Europe, Accelerating PFA Adoption

Event summary

  • Johnson & Johnson received CE Mark approval and launched VARIPULSE Pro in Europe.
  • VARIPULSE Pro utilizes a new pulse sequence that is 5x faster than the previous sequence while maintaining equivalent lesion size.
  • The new platform integrates with the CARTO 3 System for advanced mapping and lesion delivery.
  • Initial cases are being performed under the VARIPURE multicenter study, with 12-month interim results to be presented at EHRA.

The big picture

The European launch of VARIPULSE Pro underscores J&J’s commitment to expanding its presence in the rapidly growing pulsed field ablation market, which addresses the significant unmet need in atrial fibrillation treatment. PFA represents a less invasive alternative to traditional ablation procedures, and J&J’s integration with the CARTO mapping system aims to enhance precision and efficiency. The company’s focus on generating rigorous clinical evidence will be crucial for driving adoption and solidifying its leadership position in this space.

What we're watching

Clinical Adoption
The success of VARIPULSE Pro will depend on the speed and quality of data generated by the VARIPURE study and subsequent clinical trials, which will influence physician adoption.
US Approval
The timeline for FDA approval in the United States remains uncertain, and will be a key indicator of the platform’s overall potential.
Competitive Landscape
The emergence of competing PFA technologies could erode J&J’s market share if VARIPULSE Pro’s advantages are not clearly demonstrated and sustained.

J&J Expands PFA Reach, Targets Untreated Atrial Fibrillation in Peru

Event summary

  • Johnson & Johnson has launched its VARIPULSE pulsed field ablation (PFA) technology in Peru, expanding its presence in Latin America.
  • The technology is intended for treating drug-refractory paroxysmal atrial fibrillation, a condition affecting over 50 million people globally.
  • Clinica Delgado, part of the AUNA group, will be a key institution implementing the new technology.
  • VARIPULSE offers integrated mapping and ablation, reducing fluoroscopy exposure and improving procedural efficiency.
  • Peru is the latest country in Latin America to adopt the PFA technology, following others already using it in international reference centers.

The big picture

Johnson & Johnson’s expansion into Peru with VARIPULSE underscores the growing demand for minimally invasive cardiac arrhythmia treatments, particularly in regions with high rates of untreated atrial fibrillation. This move positions J&J to capitalize on a significant unmet need and reinforces its strategy of targeting specialized procedures with advanced technology. The launch also highlights the increasing importance of Latin America as a growth market for medical device companies, driven by rising healthcare expenditure and an aging population.

What we're watching

Adoption Rate
The speed at which Clínica Delgado and other Peruvian institutions integrate VARIPULSE will indicate the technology’s acceptance and potential market penetration within the country.
Competitive Landscape
How competing ablation technologies and companies will respond to J&J’s expanded presence in the Latin American market, particularly regarding pricing and features, warrants observation.
Regulatory Scrutiny
Increased adoption of advanced medical technologies like PFA may draw greater regulatory scrutiny regarding long-term patient outcomes and cost-effectiveness in Peru and other Latin American markets.

J&J's TECNIS PureSee Lens Approval Signals Shift in Cataract Surgery Focus

Event summary

  • Johnson & Johnson received FDA approval for TECNIS PureSee, an extended depth of focus (EDOF) intraocular lens (IOL) for cataract surgery.
  • TECNIS PureSee is the first U.S. FDA-approved EDOF IOL with no warning on loss of contrast sensitivity.
  • The lens aims to address both cataract-related vision loss and presbyopia, reducing reliance on glasses.
  • Approximately 94 million people aged 50+ globally experience vision impairment potentially correctable through lens replacement surgery.
  • Nearly half a million eyes worldwide have already used TECNIS PureSee.

The big picture

The approval of TECNIS PureSee reflects a broader trend toward more sophisticated IOLs that address presbyopia alongside cataract correction, catering to an aging population seeking improved visual outcomes. J&J's move strengthens its position in the $3 billion+ global IOL market, but faces competition from established players and emerging technologies. The absence of a contrast sensitivity warning is a key differentiator, potentially attracting surgeons and patients prioritizing visual quality.

What we're watching

Market Adoption
The speed of adoption by surgeons and patient demand will determine TECNIS PureSee's impact on J&J's vision care revenue, particularly given the existing competitive landscape of IOLs.
Clinical Data
Long-term clinical data on contrast sensitivity and visual disturbance rates will be crucial for maintaining market share and defending against potential competitor claims.
Portfolio Synergy
J&J's ability to effectively cross-sell TECNIS PureSee alongside its other IOL offerings (Odyssey, Eyhance) will influence overall portfolio performance and market penetration.

J&J to Detail Q1 Results Amid Ongoing Portfolio Realignment

Event summary

  • Johnson & Johnson will host an investor conference call on April 14, 2026, at 8:30 AM ET.
  • CEO Joaquin Duato, CFO Joseph Wolk, and VP of Investor Relations Darren Snellgrove will lead the call.
  • The earnings press release will be available starting at 6:45 AM ET on April 14, 2026.
  • A replay of the call will be available until April 28, 2026.

The big picture

Johnson & Johnson's upcoming earnings call arrives amidst a period of significant strategic repositioning, including divestitures and a renewed focus on core healthcare segments. The company's ability to navigate ongoing legal challenges and demonstrate sustainable growth will be critical for maintaining its position as a healthcare industry leader. The call will provide insight into the effectiveness of these strategic shifts and the company's outlook for the remainder of 2026 and beyond.

What we're watching

Portfolio Focus
The call will likely address the ongoing strategic shift towards Innovative Medicine and MedTech, and the impact of divestitures on overall revenue growth.
Legal Landscape
Continued litigation surrounding talc products will remain a key area of investor scrutiny, and the call should provide updates on ongoing legal proceedings and associated costs.
Growth Trajectory
The pace at which J&J can integrate recent acquisitions and demonstrate organic growth will be crucial in sustaining investor confidence and justifying the company's valuation.

J&J Invests $1B in Pennsylvania Cell Therapy Manufacturing

Event summary

  • Johnson & Johnson is investing over $1 billion in a new cell therapy manufacturing facility in Montgomery County, Pennsylvania.
  • The facility will create over 500 biomanufacturing jobs and more than 4,000 construction jobs.
  • This investment is part of J&J’s previously announced $55 billion U.S. investment plan through early 2029.
  • J&J already has a significant presence in Pennsylvania, with approximately $10 billion in annual economic impact.
  • Pennsylvania's economic development strategy, including reduced red tape and workforce investment, attracted the investment.

The big picture

J&J’s investment underscores the growing importance of cell therapy as a treatment modality for cancer and other diseases, and the increasing competition for advanced manufacturing capabilities. The move also highlights the role of state-level economic development initiatives in attracting large-scale biomanufacturing investments, potentially reshaping the geographic distribution of pharmaceutical production. Pennsylvania's aggressive economic development strategy is a notable shift, and other states will likely attempt to replicate its success.

What we're watching

Regulatory Headwinds
Increased state-level incentives for biomanufacturing could intensify competition for investment among states, potentially impacting future site selection decisions.
Execution Risk
The success of the facility will depend on J&J’s ability to rapidly scale cell therapy production and meet anticipated demand, given the complexity of these manufacturing processes.
Governance Dynamics
How J&J balances this domestic investment with its broader global manufacturing footprint and R&D priorities will signal its long-term strategic focus.

J&J's OMNY-AF Data Shows 100% Procedural Success in Pilot Study

Event summary

  • Johnson & Johnson presented 12-month pilot data from the OMNY-AF study, showing 100% acute procedural success with no adverse events.
  • The OMNY-AF study, involving 30 patients, achieved 90% primary effectiveness at 12 months, with 56.7% of cases requiring zero fluoroscopy.
  • Data on J&J’s VARIPULSE Platform demonstrated a neurovascular event rate of 0.22% after workflow enhancements and irrigation optimization.
  • The OMNY-AF study is a prospective, single-arm, multi-center trial across the U.S. and Australia, aiming to enroll up to 440 subjects.

The big picture

J&J's early OMNY-AF data represents a significant step in the development of pulsed field ablation (PFA) technology, a relatively new approach to treating atrial fibrillation. While the initial results are promising, the limited sample size and single-arm design necessitate cautious interpretation. The broader PFA market is still nascent, but holds potential to disrupt existing ablation techniques, which have historically faced challenges with efficacy and safety.

What we're watching

Clinical Adoption
The speed of adoption for the OMNY-AF platform will depend on broader clinical validation and acceptance beyond the initial pilot cohort, particularly given the relatively small sample size.
Regulatory Pathway
The regulatory pathway for the OMNY-AF platform remains uncertain, and approval timelines will be a key factor in determining commercial viability.
Competitive Landscape
The success of J&J’s pulsed field ablation technologies will be challenged by existing and emerging competitors in the atrial fibrillation treatment space, requiring ongoing differentiation and innovation.

J&J to Address Investors at TD Cowen Healthcare Conference

Event summary

  • Johnson & Johnson will participate in the TD Cowen 46th Annual Health Care Conference.
  • The conference will be held on March 3rd, 2026.
  • Management will participate in a Fireside Chat at 11:10 a.m. Eastern Time.
  • A live audio webcast will be available on J&J’s Investor Relations website.

The big picture

Johnson & Johnson’s participation in the TD Cowen conference follows the recent spin-off of its consumer health division, Kenvue, marking a significant strategic shift for the company. The Fireside Chat will be a key event for investors to assess J&J’s future direction and financial outlook. Management’s commentary will be closely analyzed for signals regarding R&D investment, potential acquisitions, and overall strategic priorities.

What we're watching

Strategic Focus
The content of the Fireside Chat will reveal management’s priorities following the Kenvue spin-off and subsequent restructuring, and whether they will emphasize specific therapeutic areas or geographic regions.
Pipeline Updates
The conference provides an opportunity for J&J to highlight progress on key pipeline assets, and the market will scrutinize commentary for any signs of delays or unexpected challenges.
Financial Outlook
Investor sentiment will be influenced by any guidance provided regarding revenue growth, margin expansion, and capital allocation strategies in the post-Kenvue environment.

J&J Commits $120M to MedTech Access, Signals Shift to Workforce Support

Event summary

  • Johnson & Johnson (J&J) has donated $100 million in MedTech products since 2020 to improve access to specialized care globally.
  • J&J plans to contribute an additional $20 million in 2026 for programs and impact investments focused on health worker empowerment.
  • The initiatives are part of J&J CareCommunity, a social impact platform focused on health worker support and care access.
  • J&J and its partners aim to train over 300,000 healthcare professionals annually to utilize new technologies and improve surgical care.
  • J&J is collaborating with organizations like Operation Smile and the American Heart Association to expand access to care and training.

The big picture

J&J’s increased focus on health worker empowerment and access programs signals a strategic shift beyond simply providing medical devices. This move addresses a critical bottleneck in healthcare delivery – the shortage of skilled professionals – and aligns with growing pressure for corporations to address social determinants of health. The $120 million commitment, while substantial, represents a relatively small fraction of J&J’s overall MedTech revenue, suggesting this is more about brand building and stakeholder management than a core business strategy.

What we're watching

Program Sustainability
The reliance on partnerships for program delivery raises questions about the long-term sustainability of these initiatives if funding or partner priorities shift.
Impact Measurement
Demonstrating a quantifiable return on investment for these social impact programs will be crucial for justifying continued funding and attracting further partnerships.
Competitive Response
Other MedTech firms may increase similar philanthropic efforts to bolster their brand image and attract talent, potentially intensifying competition for partnerships and resources.

J&J Secures Tariff Exemption in Drug Pricing Agreement with Trump Administration

Event summary

  • Johnson & Johnson reached a voluntary agreement with the Trump Administration to improve U.S. patient access to medicines and lower costs.
  • The agreement includes an exemption for J&J’s pharmaceutical products from tariffs.
  • J&J will participate in TrumpRx.gov, a direct-to-patient platform offering discounted medicines.
  • The company is committing $55 billion to U.S. manufacturing, R&D, and technology investments by early 2029.
  • J&J is announcing two new U.S. manufacturing facilities in Pennsylvania and North Carolina, alongside progress on a $2 billion biologics facility in Wilson, North Carolina.

The big picture

This agreement represents a significant shift in the U.S. government's approach to drug pricing, potentially setting a precedent for increased industry scrutiny and direct intervention. J&J’s willingness to participate suggests a strategic calculation that the benefits of tariff relief and access to a direct-to-patient channel outweigh the potential for future regulatory pressure. The $55 billion investment underscores a commitment to domestic manufacturing, aligning with broader geopolitical trends favoring onshoring and supply chain resilience.

What we're watching

Tariff Impact
The specific terms of the tariff exemption remain confidential, and the long-term implications for J&J’s supply chain and pricing strategy require further clarification.
TrumpRx.gov
The success of TrumpRx.gov in driving volume and managing costs will be critical to J&J’s ability to maintain profitability while adhering to the agreement.
Political Risk
Changes in administration could lead to a renegotiation or termination of the agreement, creating uncertainty for J&J’s U.S. operations and investment plans.

J&J Seeks FDA Approval for OTTAVA Robotic System, Expanding Surgical Automation

Event summary

  • Johnson & Johnson submitted the OTTAVA™ Robotic Surgical System to the FDA for De Novo classification in January 2026.
  • The submission is based on data from an Investigational Device Exemption (IDE) study completed in early 2025 at Memorial Hermann-Texas Medical Center.
  • OTTAVA is designed for multiple procedures in general surgery within the upper abdomen, including gastric bypass and hiatal hernia repair.
  • A second IDE trial for inguinal hernia repair was approved in late 2025.
  • The system integrates Ethicon surgical instrumentation and is intended to connect with Johnson & Johnson’s Polyphonic™ digital ecosystem.

The big picture

Johnson & Johnson’s OTTAVA system represents a significant investment in the growing robotic surgery market, which is projected to reach billions in the coming years. The De Novo pathway suggests a differentiated approach, potentially bypassing some regulatory hurdles but also signaling a degree of novelty that could face scrutiny. The integration with the Polyphonic digital ecosystem hints at a broader strategy to capture data and enhance surgical workflows, but also introduces complexity and dependency on a nascent digital platform.

What we're watching

Regulatory Approval
The FDA's De Novo classification process will be critical; a protracted review could delay commercialization and impact investor expectations.
Market Adoption
The success of OTTAVA will depend on surgeon adoption and integration into existing hospital workflows, potentially requiring significant training and support.
Competitive Landscape
How J&J positions OTTAVA against established robotic surgery platforms like Intuitive Surgical’s da Vinci system will determine its market share and long-term viability.

J&J Acquires Halda Therapeutics for $3.05 Billion, Bolstering Oncology Pipeline

Event summary

  • Johnson & Johnson completed the acquisition of Halda Therapeutics OpCo, Inc. for $3.05 billion in cash.
  • Halda possesses a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform for oral cancer therapies.
  • HLD-0915, a clinical-stage therapy for prostate cancer utilizing the RIPTAC™ platform, is among the assets acquired.
  • The acquisition is expected to result in a dilution of approximately $0.20 per share, split between Q4 2025 and 2026.
  • J&J will discuss the financial impact during its Q4 2026 earnings call on January 21, 2026.

The big picture

This $3.05 billion acquisition underscores the ongoing consolidation within the biotechnology sector, as large pharmaceutical companies seek to bolster their pipelines with innovative technologies. The RIPTAC™ platform represents a novel approach to targeted cancer therapy, potentially addressing a significant unmet need for oral treatments and overcoming resistance mechanisms. J&J's move highlights the continued focus on oncology, a high-value area despite increasing regulatory scrutiny and pricing pressures.

What we're watching

Execution Risk
The success of this acquisition hinges on J&J’s ability to effectively integrate Halda’s RIPTAC™ platform and advance its pipeline candidates, particularly given the anticipated earnings dilution.
Clinical Progress
The clinical trial outcomes for HLD-0915 and other RIPTAC™-based therapies will be critical in determining the long-term value of the acquisition and J&J’s oncology portfolio.
Platform Expansion
How J&J leverages the RIPTAC™ platform beyond oncology, as suggested in the release, will indicate the breadth of its strategic vision and potential for future growth.
CID: 311